A high-level delegation from business facilitation company Naseba invited for the Annual Investor Meeting of E-fung Capital, supporting deals in pharmaceuticals and portfolio companies
DUBAI – With ambitions to boost private equity and venture capital investment in China, a high-level delegation from international business facilitation company Naseba, has attended the annual investor meeting of E-fung Capital, held on 8 March in Shenzhen.
The meeting hosted more than 200 limited partners (LPs), including pharmaceutical firms, institutional and individual investors, C-level management of E-fung’s portfolio companies and overseas strategic partners.
Drawing on Naseba’s extensive experience facilitating deal flows across East Asia, the Middle East, and Africa, the firm will support E-fung Capital’s Chinese investors to source qualified overseas investment opportunities.
Bridging the overseas investment gap, Naseba will specifically focus on supporting the LP network, with global deal flows in AI, blockchain, hi-tech, med-tech, health information systems, pharma and medical device ventures.
Leading the Naseba delegation at the meeting and driving the firm’s expansion in China, Immanuel Reginald, Senior Investor Analyst from Naseba, met with E-Fung Chief Science Office and Partner, Dr. Weimin Xiao and other senior executives during the meeting to outline a clear strategy for facilitating their deal flow needs.
Dr. Xiao said:” With the growing health care demands in China, we need to introduce more and more new drugs and medical devices. With the economic development in China, more and more funds in China need to look for good investment targets abroad. I believe that the collaboration with Naseba will help us to become one of the best healthcare investors in the world.”
Immanuel said: “China is the world’s second-largest economy and last year Asian markets enjoyed their strongest performance since the 2009 financial crisis, with 2018 on track to deliver similar results. We at Naseba have huge faith in the Chinese economy and are fully aware of the huge demand from the firms we work with to move into the Chinese market, specifically those in Europe and the US. As investors around the globe seek out the most promising opportunities, interest in China is reaching an all-time high. E-Fung’s partnership with Naseba will bring the firm’s investors an unparalleled chance to source qualified overseas investments– for those looking to break into the Chinese market, this is a once in a decade opportunity.”
During the same visit, analysts from Naseba’s investor services arm also presented up to 10 qualified healthcare focused companies to a select group of institutional investors and pharmaceutical firms.
Since first arriving in China six years ago, Naseba has gradually built strong relationships with leading prominent private equity and venture capital firms in mainland China, such as E-fung.
E-fung, one of the most prominent VC firms in China, specialises in early stage and growth capital ventures, primarily invests in healthcare and biopharmaceuticals. The firm also invests in technology, media, telecommunications, environmental protection, and new materials.
Digital Marketing Manager
+971 44 55 79 20
Naseba creates growth opportunities, connecting people, partners and ideas. Focused on deal facilitation, it helps clients: raise capital, close sales, enter new markets, secure partners and educate workforces. Naseba’s goal is to create opportunity and add economic value at every stage of its client’s journey. It does this through three key areas: investor services, commercial services, and leadership services.
Since 2002, Naseba has facilitated more than a billion dollars’ worth of deals and has connected over 100,000 global executives through more than 1,000 proprietary business platforms in liquid growth markets.
Naseba is a signatory of the Women’s Empowerment Principles – Equality Means Business, produced and disseminated by the United Nations Entity for Gender Equality and the Empowerment of Women (UN Women) and the United Nations Global Compact.